RotaTeq®, a pentavalent rotavirus vaccine: Efficacy and safety among infants in Europe
Section snippets
Background
Rotavirus is a leading cause of mortality from severe acute gastroenteritis in infants and young children worldwide, with about 600,000 deaths in children less than 5 years old every year [1], [2], [3]. Although deaths are rare in industrialized countries, in the pre-vaccine era, rotavirus was estimated to be responsible for 223,000 hospitalizations and 1.8 million outpatient visits in children <5 years of age every year in these countries [1].
An analysis of published data before rotavirus
Methods
REST was a randomized, blinded, placebo-controlled trial conducted from 2001 to 2005, and full methodological details are reported elsewhere [14], [18]. Healthy infants received the first oral dose of either RotaTeq® or placebo at 6–12 weeks of age and subsequently two more doses at 4–10-week intervals, up to 32 weeks of age.
European cohort: safety after any dose
Adverse events reported for the safety population enrolled in Europe within 42 days after any dose of RotaTeq® or placebo are summarized in Table 1. There were no clinically relevant differences in any of the safety outcomes between the vaccine and placebo recipients.
Finnish cohort: safety after first dose
The symptoms reported within seven days after dose 1 in the Finnish subset, who received the first dose of RotaTeq® or placebo without concomitant vaccinations, are shown in Table 2. There were no statistically significant
Discussion
The results from these post hoc analyses of the REST European data show that RotaTeq® has excellent clinical efficacy against severe rotavirus disease. The vaccine also reduced the severity of RVGE as shown by a downward shift in the clinical severity scores (Fig. 2) and change in the type of health care encounters towards less intensive care settings among vaccine recipients as compared with placebo recipients (Table 3). The rates of healthcare encounters for RVGE varied by country due to
Acknowledgements
REST was funded by Merck & Co; RotaTeq® is a vaccine commercialized in Europe by Sanofi Pasteur MSD and elsewhere by Merck & Co.
The authors would like to thank Gary Koch for statistical assistance, Communigen, Oxford, UK for preparing the first draft (funded by Sanofi Pasteur MSD) and Tin Tin Htar Myint, Margaret Haugh, Patrick Palluel and Max Ciarlet for comments and suggestions on drafts of this manuscript.
Contributions: TV: trial design, data collection, data analysis, interpretation of
References (29)
- et al.
Rotavirus bacines: current prospects and future challenges
Lancet
(2006) Clinical trials of live oral rotavirus vaccines: the Finnish experience
Vaccine
(1993)- et al.
Rotavirus vaccines: considerations for successful implementation in Europe
Lancet Infect Dis
(2006) - et al.
Rotavirus vaccines: current prospects and future challenges
Lancet
(2006) - et al.
Effects of the potency and composition of the multivalent human–bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants
Vaccine
(2006) - et al.
Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study
Lancet
(2007) - et al.
A regional analysis of the efficacy of a pentavalent rotavirus vaccine (RotaTeq®) in reducing rotavirus-associated health care utilization based on data from 11 countries
IJID
(2007) - et al.
Safety, efficacy, and immunogenicity of a live, quadrivalent human–bovine reassortant rotavirus vaccine in healthy infants
J Pediatr
(2004) - et al.
The integrated phase III safety profile of the pentavalent human–bovine (WC3) reassortant rotavirus vaccine
Int J Infect Dis
(2007) - et al.
Global illness and deaths caused by rotavirus disease in children
Emerg Infect Dis
(2003)
Rotavirus and severe childhood diarrhea
Emerg Infect Dis
Burden of rotavirus disease in European Union countries
Pediatr Infect Dis J
The paediatric burden of rotavirus disease in Europe
Epidemiol Infect
Clinical consequences of rotavirus acute gastroenteritis in Europe, 2004–2005: the REVEAL study
J Infect Dis
Cited by (84)
Rotavirus disease and health care utilisation among children under 5 years of age in highly developed countries: A systematic review and meta-analysis
2021, VaccineCitation Excerpt :Our electronic search identified 4033 records after removing duplicates, of which we selected 1336 based on screening of titles and abstracts. Of these, we included 77 full-text manuscripts reporting on 74 studies in the systematic review [26–100] (Fig. 2). The included studies were conducted in 21 different countries in North America, Europe, Asia and Oceania.
Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials
2019, The Lancet Infectious DiseasesCitation Excerpt :We excluded trials that evaluated special groups, such as populations with high HIV prevalence46 and breastfed infants.47 We excluded the Finnish Extension Trial48,49 because the results could not be disentangled from a pooled estimate for five European countries reported separately.42 For the pooled analysis we focused on infant schedules, so excluded the neonatal RotaShield trial50 in Ghana and the neonatal schedule group of the RV3-BB trial15 in Indonesia.
Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia
2017, VaccineCitation Excerpt :Our findings focused on impacts on changes in both coded-RV and unspecified AGE hospitalisations, as we believe these are more likely to show the full impact of the rotavirus vaccination program. The wider vaccine impact on all AGE hospitalisations from any cause is supported by clinical trial data [35,36] which likely reflects the presence of both diagnosed and undiagnosed rotavirus cases amongst this broad disease category. Our observed decline of ∼50% in unspecified AGE hospitalisations (which includes undiagnosed rotavirus illness) for children <5 years was of similar magnitude to declines observed in all-cause AGE admissions in the United Kingdom [37] and the United States [38–42].